Bone Biologics 

$5.19
34
+$2.09+67.42% Friday 18:44
-$1.14-21.97%Friday 20:00After hours

Statistics

Day High
5.26
Day Low
4.05
52W High
35.95
52W Low
3.5
Volume
-
Avg. Volume
-
Mkt Cap
14.3M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

2DecExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-3.24
-2.22
-1.21
-0.19
Expected EPS
-0.19
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-3.11MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BBLGW. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Stryker
SYK
Mkt Cap126.84B
Stryker Corporation is a leading medical technology company that offers a range of orthopedic products, competing directly with Bone Biologics in the bone repair and regeneration market.
Zimmer Biomet
ZBH
Mkt Cap19.25B
Zimmer Biomet Holdings, Inc. specializes in musculoskeletal healthcare, offering products that compete in the orthopedic sector, similar to Bone Biologics' offerings.
Medtronic
MDT
Mkt Cap116.77B
Medtronic plc provides medical technologies, services, and solutions, including bone healing and regeneration products, making it a competitor in the same space as Bone Biologics.
Boston Scientific
BSX
Mkt Cap67.88B
Boston Scientific Corporation offers products in various medical fields, including orthopedic surgery, competing with Bone Biologics in areas like bone growth and repair.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its subsidiary DePuy Synthes, offers a wide range of orthopedic products, directly competing with Bone Biologics in the field of bone health and regeneration.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc., while primarily known for its biopharmaceutical products, has ventured into cell therapy, which could potentially compete with Bone Biologics' regenerative medicine approaches.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc., with its broad range of healthcare products, has the potential to compete in the orthopedic and regenerative medicine space, overlapping with Bone Biologics' market.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie Inc. engages in the discovery, development, manufacture, and sale of a broad line of pharmaceuticals, including treatments that could compete with Bone Biologics in bone health and regeneration.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. focuses on human therapeutics, including osteoporosis treatment and bone health products, making it a competitor in the bone regeneration market alongside Bone Biologics.

About

Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.
Show more...
CEO
Jeffrey Frelick
Employees
2
Country
United States
ISIN
US0980701546

Listings

0 Comments

Share your thoughts

FAQ

What is Bone Biologics stock price today?
The current price of BBLGW is $5.19 USD — it has increased by +67.42% in the past 24 hours. Watch Bone Biologics stock price performance more closely on the chart.
What is Bone Biologics stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Bone Biologics stocks are traded under the ticker BBLGW.
Is Bone Biologics stock price growing?
BBLGW stock has fallen by -8.95% compared to the previous week, the month change is a -32.6% fall, over the last year Bone Biologics has showed a -51.9% decrease.
What is Bone Biologics market cap?
Today Bone Biologics has the market capitalization of 14.3M
When is the next Bone Biologics earnings date?
Bone Biologics is going to release the next earnings report on December 02, 2026.
What were Bone Biologics earnings last quarter?
BBLGW earnings for the last quarter are -0.43 USD per share, whereas the estimation was -0.43 USD resulting in a +0% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Bone Biologics revenue for the last year?
Bone Biologics revenue for the last year amounts to 0 USD.
What is Bone Biologics net income for the last year?
BBLGW net income for the last year is -3.11M USD.
How many employees does Bone Biologics have?
As of September 06, 2026, the company has 2 employees.
In which sector is Bone Biologics located?
Bone Biologics operates in the Health & Wellness sector.
When did Bone Biologics complete a stock split?
The last stock split for Bone Biologics was on June 10, 2025 with a ratio of 1:6.
Where is Bone Biologics headquartered?
Bone Biologics is headquartered in BURLINGTON, United States.